Question

rythromycin is a drug that has been proposed to possibly lower the risk of premature delivery. A related area of interest is its association with the incidence of side effects during pregnancy. Assume that 30% of all pregnant women complain of nausea between the 24th and 28th week of pregnancy. Furthermore, suppose that of 199 women who are taking erythromycin regularly during this period, 70 complain of nausea. The p-value for testing the hypothesis that incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman is 0.0559. At the 1% significance level, what is the conclusion of the above hypothesis test?

(A) We conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is less than .02   (B) We conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is greater than or equal to 0.01   (C) We conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is less than 0.01   (D) We cannot conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is less than 0.01   (E) We cannot conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is greater than or equal to 0.01   (F) We cannot conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is less than .02   (G) We cannot conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is greater than or equal to .02   (H) We conclude that the incidence rate of nausea for the erythromycin group is greater than for a typical pregnant woman since the p-value is greater than or equal to .02

Answer 1